ClinicalTrials.gg
CompletedNCT01678456AFNET A7Updated Sep 22, 2020

Prospective Registration and Assessment of Serious Adverse Events Within the AFNET

An observational study in Atrial Fibrillation, Assessment of Serious Advers Events and Thromboembolic and Bleeding Complications, sponsored by Atrial Fibrillation Network. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-22.

Sponsored by Atrial Fibrillation Network · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
13,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Atrial Fibrillation by Atrial Fibrillation Network — 2 open to participants now, 2 under way, none of them phase 3. Atrial Fibrillation · Atrial Fibrillation Network.

Started
2004
the only one that year
Observational
3 of 13
none open now
Registered
2nd of 13
by date

Among the 13 studies in Atrial Fibrillation by Atrial Fibrillation Network, this one is the only one that started in 2004, is one of 3 observational ones, and was the 2nd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

2 of the 13 studies in Atrial Fibrillation by Atrial Fibrillation Network are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Atrial Fibrillation by Atrial Fibrillation Network, or all of them as a file.
02

Study summary

Prospective registration and independent assessment of SAE associated with atrial fibrillation such as thromboembolic events, and other cardiac and noncardiac complications by a Critical Event Committee.

Read the detailed description

Atrial fibrillation (AF), the most common sustained rhythm disturbance, is associated with a significantly enhanced mortality and morbidity due to thromboembolic events, and other cardiac and noncardiac complications. Therefore the "Network of Competence on Atrial Fibrillation (AFNET)" supported by the German Ministry for Education and Research (BMBF) was established in order to collect clinical data on patients (pts) with AF (paroxysmal, persistent, permanent) over a study period of 6 years with an expected sample size of 12,000 pts. Incidence, clinical relevance and outcome after SAE is recorded and assessed by a Critical Event Committee (CEC).

The CEC-members (experts in cardiology and neurology) defined as SAE any death with or without relationship to AF, cardio-embolic events (stroke, peripheral arterial embolism), bleeding complications due to antithrombotic therapy, acute heart failure, syncope, resuscitation; additionally, the complication of interventional strategies for AF-treatment and other AF-independent SAEs.

Over a 3-year follow-up period, during 6-monthly and unscheduled visits, the SAEs are systematically documented, blinded and their relationship to AF will be interpreted in detail by the CEC.

03

Conditions studied

  • Atrial Fibrillation
  • Assessment of Serious Advers Events
  • Thromboembolic and Bleeding Complications
  • Complications of Antiarrhythmic Drugs or Invasive Procedures
  • Assessment by a Critical Event Committee

Keywords

  • Atrial Fibrillation
  • Critical Event Committee
  • Serious adverse events
  • Thromboembolic complications
  • Cardiac and noncardiac complications
  • Bleeding complications
  • Acute heart failure
  • Syncope
  • Resuscitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Real-life population Patients with atrial fibrilation documented within the last 12 months before enrollment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Atrial fibrillation documented by not older then one year
  • Age > 18 years

Exclusion criteria

Exclusion Criteria:

  • none
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
13,000 participants (actual)
06

Study locations

1 site
  • Staedt. Klinikum, Department of Cardiology
    Brandenburg, 14770, Germany
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2004, a primary completion of Oct 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2005
First posted
Sep 5, 2012
Start
Feb 2004
Primary completionActual
Oct 2012
CompletionActual
Dec 2012
Last update
Sep 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT01678456
Lead sponsor
Atrial Fibrillation Network
Responsible party
Sponsor
First posted
Sep 5, 2012
Start date
Feb 2004
Primary completion
Oct 2012
Completion
Dec 2012
Last update
Sep 22, 2020

Study contacts

Michael Oeff, Professor
principal investigator · SAE-Zentrum Brandenburg/Havel Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion